Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible
PPHMP
PPHMP was delisted on the 5th of January, 2018.
1 hedge funds and large institutions have $2K invested in Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QAM
QCI Asset Management
Pittsford,
New York
|
+$1.91K |
Top Sellers
PPHMP Hedge Fund Activity: Q4 2017 in Review
1 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible (PPHMP) for Q4 2017, worth a combined $2K.
Buyers outnumbered sellers: 1 fund opened new PPHMP positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was QCI Asset Management, opening a new position worth an estimated $1.91K.
- 1 institutional investor held Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible (PPHMP) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $2K of Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible stock for Q4 2017.
- 1 fund opened new Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible positions in Q4 2017 and 0 closed out, a net change of +1 holder.
- The largest Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible buyer in Q4 2017 was QCI Asset Management, an estimated $1.91K added.
Based on aggregated 13F filings for Q4 2017.